KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Depreciation & Amortization (CF) (2016 - 2025)

Novavax (NVAX) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $5.1 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 59.06% year-over-year to $5.1 million; the TTM value through Dec 2025 reached $27.6 million, down 43.06%, while the annual FY2025 figure was $27.6 million, 43.06% down from the prior year.
  • Depreciation & Amortization (CF) reached $5.1 million in Q4 2025 per NVAX's latest filing, down from $6.6 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $12.7 million in Q3 2024 and bottomed at $2.3 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $8.0 million, with a median of $8.0 million recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 191.97% in 2022, then plummeted 59.06% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.7 million in 2021, then skyrocketed by 96.68% to $7.2 million in 2022, then soared by 49.46% to $10.8 million in 2023, then increased by 15.96% to $12.5 million in 2024, then tumbled by 59.06% to $5.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $5.1 million in Q4 2025, $6.6 million in Q3 2025, and $7.6 million in Q2 2025.